Oncotarget

Research Papers:

The network of DAB2IP-miR-138 in regulating drug resistance of renal cell carcinoma associated with stem-like phenotypes

Eun-Jin Yun _, Jiancheng Zhou, Chun-Jung Lin, Shan Xu, John Santoyo, Elizabeth Hernandez, Chih-Ho Lai, Ho Lin, Dalin He and Jer-Tsong Hsieh

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:66975-66986. https://doi.org/10.18632/oncotarget.17756

Metrics: PDF 647 views  |   HTML 1221 views  |   ?  


Abstract

Eun-Jin Yun1,*, Jiancheng Zhou1,2, Chun-Jung Lin1, Shan Xu1,3, John Santoyo1, Elizabeth Hernandez1, Chih-Ho Lai4, Ho Lin5, Dalin He3 and Jer-Tsong Hsieh1,6,*

1Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA

2Department of Urology, Shaanxi Provincial People’s Hospital, Xi’an, Shaanxi 710068, China

3Department of Urology, The First Affiliated Hospital, Medical School of Xi'an Jiaotong University, Xi'an 710049, China

4Department of Microbiology and Immunology, Chang Gung University, Taoyuan 333, Taiwan

5Department of Life Sciences, National Chung Hsing University, Taichung 402, Taiwan

6Graduate Institute of Cancer Biology, China Medical University Hospital, Taichung 40447, Taiwan, Republic of China

*These authors contributed equally to this work

Correspondence to:

Eun-Jin Yun, email: eun-jin.yun@utsouthwestern.edu

Jer-Tsong Hsieh, email: jt.hsieh@utsouthwestern.edu

Keywords: miR-138, DAB2IP, cancer stem cell, drug resistance

Received: March 21, 2017     Accepted: April 27, 2017     Published: May 09, 2017

ABSTRACT

Targeted therapy is a standard of care for metastatic renal cell carcinoma (RCC) but the response rate is not overwhelmed, which only prolongs a short survival of patients due to the onset of therapeutic resistance. Although the mechanisms are not fully understood, the presence of cancer initiating cells (CIC) may underlie the drug resistance. Nevertheless, identifying CIC phenotypes with its biomarkers in RCC appear to be diverse and controversial from many reports. In this study, we took a different approach to focus on the regulatory mechanism in RCC-CIC and unveil DAB2IP-mediated miR-138 expression that plays a critical role in modulating stem-like phenotypes in RCC via targeting the ABC transporter (ABCA13) as well as oncogenic histone methyltransferase EZH2 while down regulation of miR-138 gene expression in RCC is due to epigenetic gene silencing by DNA methyltransferase 1 (DNMT1). We also characterize the individual mechanism by which ABCA13 in RCC-CIC contributes to its drug resistance and. EZH2 maintain stem-like phenotypes. Noticeably, elevated expression of ABCA13 and EZH2 is correlated with overall survival of RCC patients, which can be used as potential prognostic markers. Taken together, this study demonstrates a potent and unique pathway of DAB2IP-mediated miR-138 in modulating CIC phenotypes during RCC progression and also offers a new therapeutic strategy of targeting drug resistant RCC.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 17756